Identification of Hepatitis C Virus NS5A Inhibitors
Julie A. Lemm(Bristol-Myers Squibb (United States)), Min Gao(Shandong First Medical University), Mengping Liu(China University of Geosciences (Beijing)), Richard J. Colonno(Assembly Biosciences (United States)), Nicholas A. Meanwell(Mario Negri Institute for Pharmacological Research), Donald R. O’Boyle(Bristol-Myers Squibb (United States)), Denis R. St. Laurent(Bristol-Myers Squibb (United States)), Peter T. Nower, J. Romine(Bristol-Myers Squibb (United States)), Michael H. Serrano‐Wu(Broad Institute), Lawrence B. Snyder(Arvinas (United States)), Milind Deshpande(Achillion Pharmaceuticals (United States)), Scott Martin(Bristol-Myers Squibb (United States))
Cited by 196
Related Papers
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
|Nature|2010|940
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
|Gastroenterology|2006|414
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348
Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
|Antimicrobial Agents and Chemotherapy|2006|239